Tag: carcinoid treatments

One Step Closer in the US to Peptide Receptor Radionuclide Therapy, PRRT, for Neuroendocrine Cancers
The clock is ticking!! With Advanced Accelerator Applications’ completed New Drug Application (NDA) submission of Lutathera to the U.S. Food and Drug Administration last week, a decision from the FDA is expected by early 2017. Additionally, an Expanded…
READ MORE
December Luncheon with the Experts in New York City for the Carcinoid and Neuroendocrine Tumor Community
Carcinoid and neuroendocrine tumor (NET) patients have a unique opportunity to hear from three medical experts during Lunch with the Experts in New York City on Sunday, December 6, 2015. This special program was initiated and is sponsored by the Big Apple…
READ MORE
In Memoriam: Edda Gomez-Panzani, MD
It is with deep sorrow that we learned of the passing of Edda Gomez-Panzani, MD on June 30, 2015. The NorCal CarciNET Community shared a tribute to Edda who “was instrumental in gaining FDA approval for Somatuline (lanreotide) for NETs patients …
READ MORE
DENIED: Michael Farris’ Journey with Insurance for Neuroendocrine Cancer Treatment
The good news is the very positive result at the end – but the road to getting insurance coverage for Michael Farris’ participation in the PRRT (peptide receptor radionuclide therapy) clinical trial at Excel Diagnostics in Houston, Texas, was fraught…
READ MORE
Zebra Talk — A Handbook for Newly Diagnosed Carcinoid & Neuroendocrine Tumor Patients and Their Primary Care Physicians
There’s a terrific new resource for carcinoid and neuroendocrine tumor patients and their primary care physicians entitled Zebra Talk. According to Suzi Garber of Bucks County, Pennsylvania, editor, the handbook “is intended as a reference for those…
READ MORE
Luncheon with the Experts in New York City — Carcinoid and Neuroendocrine Tumor Patients Are Invited!
The Big Apple Noids support group invites you to join fellow carcinoid and neuroendocrine tumor (NET) patients and three medical experts for lunch on Sunday, May 4 from 12:30 to 3:30 pm in a private dining room at Dorrian’s restaurant in Manhattan…
READ MORE
Novartis Offers New Sandostatin LAR Depot Co-Pay Assistance Program
A new co-pay assistance program for carcinoid syndrome patients taking Sandostatin® LAR Depot has been established by Novartis Pharmaceuticals Corporation, effective February 2014.
With the Sandostatin® LAR Depot Co-Pay Assistance Program, eligible…
READ MORE
Remembering Dr. Martin Luther King and Sharing the Carcinoid Cancer Foundation’s Dream
Fifty years ago today, August 28, 1963, the Rev. Dr. Martin Luther King gave his historic speech, “I Have a Dream.” That enormously powerful speech, http://youtu.be/smEqnnklfYs, still resonates with people decades later. As we listened to Dr. King’s…
READ MORE
Treating Neuroendocrine Tumors: New Patent Awarded
Herbert Chen, MD, and Muthusamy Kunnimalaiyaan, Ph.D., of the University of Wisconsin School of Medicine and Public Health in Madison, have received a patent (8,338,482) for a “Modulating Notch1 Signaling Pathway for Treating Neuroendocrine…
READ MORE
First U.S. Center to Enroll Patients in International, Multicenter Clinical Trial of Lu-177 Octreotate
Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, is the first center in the United States to start recruiting patients in a multicenter randomized clinical trial of Lu-177 Octreotate in patients with progressive midgut carcinoid. …
READ MORE